Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

What are other key findings of the WU-KONG28 study?

Source:

University of Texas M. D. Anderson Cancer Center

Journal reference:

Zhou, C., et al. (2026). First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. New England Journal of Medicine. DOI: 10.1056/nejmoa2604461. https://www.nejm.org/doi/full/10.1056/NEJMoa2604461